We report our experience in the treatment with benzoimidazole carbamates (mebendazole and albendazole) of 337 patients affected by hydatid cysts with different localizations. The treated cysts showed degenerative modifications in 50.6% of the cases after mebendazole treatment and in about 80%o after albendazole treatment. Relapses after therapy were observed in 30%o of the cases; about 95% of the recurring cysts showed good susceptibility to a further cycle of therapy with benzoimidazole carbamates. Side effects observed with either drug were not severe and always reversible, consisting mainly of abdominal pains and increased levels of transaminases in serum. Among the factors that may influence the therapeutic results are the drug employed, the age of the cysts, the age of the patient, and the localization of the cysts and their morphological characteristics. Moreover, it can be hypothesized that each hydatid cyst has an intrinsic sensitivity to benzoimidazole carbamates.
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In the early 1970s, some benzoimidazole carbamates were proved to be effective against Echinococcus granulosus and, since then, many investigators have employed mebendazole and albendazole for the treatment of human hydatid disease (4, 8, 14, 20, 21, 24, 27, 28, 31) . These drugs inhibit tubulin and induce blockage of glucose absorption, glycogen depletion, and degenerative alterations in the endoplasmic reticulum and mitochondria of the germinal layer, increasing lysosomes and producing cellular autolysis (6, 13, 18, 20, 32) .
Preliminary experimental data on natural hydatidosis in sheep treated with benzoimidazole carbamates frequently reveal an inflammatory process very similar to that observed in cases of spontaneous recovery on histological examination of cysts (2) . These data may suggest that benzoimidazole carbamates do not simultaneously affect different parts of hydatid cysts but that they first attack external layers of the membrane, which leads to a marked inflammatory reac-. tion altering the parasite-host equilibrium until the protoscolices and germinal layers gradually become devitalized (2) .
After encouraging experimental results observed both in vitro and in laboratory animals for the treatment of adult and larval stages of cestodes (6, 12, 15, 17) , mebendazole, a broad-spectrum anthelmintic drug, was the first benzoimidazole carbamate used in the treatment of human hydatidosis (9, 13, 16, 20, 24, 28) .
Mebendazole is poorly absorbed after oral administration, producing low levels in plasma, even lower concentrations in cysts (levels in blood, 10%), and liver metabolism leading to inactive metabolites (28) . In this regard, experimental data for animals suggest that plasma mebendazole levels of at least 72 ng/ml should be considered effective (28) .
Albendazole is the most recent benzoimidazole compound for the treatment of human hydatid disease (21, 27) . This drug appears to be highly effective in humans and other species against several larval and adult stages of nematodes, trematodes, and cestodes (21, 25, 26) . In humans, albenda-* Corresponding author.
zole is better absorbed than mebendazole, and its hepatic metabolite, albendazole sulfoxide, is also active. Levels of this metabolite in serum may be as much as 10 times higher than those produced by equivalent therapeutic doses of mebendazole (7, 20, 21, 27) . In addition, experimental data suggest that a concentration of at least 250 p,g of albendazole per liter for 7 to 10 days or 50 ,ug/liter for 30 days in in vitro cultures is required for complete protoscolex devitalization (23) .
Results in the treatment of human hydatid disease have been encouraging, though not always comparable because of the different schedules used. To solve this problem, some years ago the World Health Organization promoted two controlled multicentric trials to evaluate the usefulness of mebendazole and albendazole according to standard criteria (33, 34) . In this paper, we report our experience in the treatment of 337 cases of human hydatid disease.
MATERIALS AND METHODS
Patients. From January 1982 to December 1991, 337 patients with hydatid cysts located in various parts of their bodies were treated; 121 of them were treated with mebendazole, and 216 were treated with albendazole. The characteristics of these patients are shown in Table 1 .
Criteria for enrollment. World Health Organization protocols were used for indications and contraindications for chemotherapy (33, 34 4 h after administration of morning doses, plasma drug levels were measured in some patients by radioimmunoassay and high-pressure liquid chromatography. Thirty-five of seventysix cysts surgically removed after medical therapy were further studied to evaluate the presence and characteristics of scolices and their eventual cystic evolution after inoculation in BALB/c mice, the morphology of membranes by optic and electron microscopy studies, and endocystic drug levels. The follow-up of the patients ranged from 6 to 103 months.
Criteria for assessment. The evaluation of the results was based on objective criteria, mainly those provided by imaging methods and, in particular, ultrasound monitoring of hepatic and abdominal cysts. To evaluate the effectiveness of therapy, the following changes were considered: the volume of the cyst (with a decrease of at least 10% up to complete disappearance), the morphology of the cyst, the increase of the solid component of the cyst (partial or total solidification corresponding to the pseudosolid ultrasonic pattern), the decrease in the number and/or size of daughter cysts, detachment and/or collapse of membranes (split wall or water lily sign), and calcification.
These findings were considered degenerative alterations of the hydatid cyst, which were probably caused by a reduced ratio between fluid secretion of the parasite and its reabsorption by the host parenchyma, in turn causing reduced endocystic pressure (5, 29) .
Some of the hydatid cysts were clearly defined and therefore easily measurable; however, some patients had widespread hydatidosis with ill-defined cysts that were difficult to Results of albendazole treatment of singly investigated cysts. On the whole, irrespective of their localization, 77.9% of the hydatid cysts treated with albendazole showed degenerative modifications (listed in "Criteria for assessment" above) after treatment; this improvement sometimes continued after treatment was stopped. After the end of therapy, 30.9% of the cysts recurred, and over one-half of the cases relapsed Tables 4 and 5 ; in these cases, the effects of therapy were evaluated by subjective rather than objective criteria.
Treatment of recurrent cysts. Table 6 illustrates the results obtained after a further cycle of treatment with mebendazole or albendazole of the cysts that recurred after treatment. These results demonstrate that recurring cysts showed good susceptibility (of about 94.9%) to a further cycle of therapy with the same drug or with the other benzoimidazole compound.
Studies of cysts removed after treatment. Data relating to the characteristics of scolices and membranes of 35 cysts surgically removed from 24 patients and examined after a cycle of therapy with mebendazole (23) and albendazole (12) are reported in Table 7 . These data demonstrate that most of the treated cysts had reduced numbers of scolices which Six children with lung hydatidosis had repeated vomica or expectoration of membranes during or soon after treatment. Vomica was observed more than once (up to three times) in two of these children. In all cases, vomica was followed by anatomic cure (i.e., disappearance of cysts); further intrapulmonary dissemination was never observed.
Immunological survey. Regarding the' immunological reactions of patients treated with mebendazole and albendazole, antibody levels detectable by routine serological tests (indirect hemagglutination, double diffusion, and counterimmunoelectrophoresis) are not correlated with therapeutic results in short-term follow-up.
DISCUSSION
Since the natural history of hydatidosis is not well documented and because of the many different factors related to both the host and the parasite, an evaluation of the results Original mebendazole treatment (30) Mebendazole follow-up (14) 11 3
Albendazole follow-up (16) 13 3 Original albendazole treatment (103) Mebendazole follow-up (4) 1 3
Albendazole follow-up (99) 94 5 a Positive, degenerative modifications of the cysts (see "Criteria for assessment" above) after treatment; negative, no modification of the cysts after treatment. observed is difficult. Furthermore, it is hard to establish objective criteria to quantify therapeutic effectiveness, especially in the cases of widespread hydatidosis. Anatomic cure, i.e., disappearance of cysts followed by restitution ad integrum, should be the ultimate goal of treatment, but it can rarely be reached after medical treatment, and in only 8% of the cases reported in this paper did all cysts disappear.
Up to now, no immunological marker of prognostic value a Several side effects were observed in some patients. Eight patients treated with mebendazole and six treated with albenzadole stopped treatment because of side effects.
b Serum glutamic oxalacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) levels were considered elevated at 20% of the normal upper limit. in a short-term follow-up has been identified, perhaps because medical treatment leads to biological recovery (death of the parasite) more often than to an anatomic cure, with persistence of the host's antigenic stimulation. In fact, in our experience, specific immunoglobulin E determination is more useful in a long-term than in a short-term follow-up (3).
More-promising results could perhaps be obtained by studying cellular immunity by the peripheral blood mononuclear cell proliferation assay (30) (which showed a decreased activity in patients with better therapeutic results) and by testing histamine release from basophils; the latter test is still being investigated (1).
In our experience, reported in previous papers, the levels of benzoimidazole carbamates in both plasma and cysts are poor and do not show a linear correlation with the effectiveness of the therapy (9, 11) .
Most of the cysts treated with benzoimidazole carbamates show degenerative modifications (volumetric reduction and/or morphological alterations, such as solidification, detaching of membranes, and calcification) whose further evolution can hardly be predicted: in some cysts these degenerative modifications progressed until the parasite's death (biological recovery), while some cysts recurred after the end of treatment.
Anatomic cure after therapy with benzoimidazole carbamates is more frequent for lung cysts of children or for cysts dating back less than 2 years, since they are more easily expectorated (10, 19) .
Calcification in liver cysts, as previously reported both by our group and by other authors (3, 31) , is generally observed later in the follow-up and is not indicative of the parasite's death.
Treatment with benzoimidazole carbamates can sometimes sterilize the cysts and kill the parasite without also causing modifications detectable by imaging methods. A prolonged follow-up period (for at least 10 years, if not for life) for patients treated with benzoimidazole carbamates is needed before a definitive evaluation of the effectiveness of the therapy can be made.
Factors influencing therapeutic results. Many factors can influence the therapeutic results, and it was possible to elaborate statistical evaluations for some. These statistics, however, must be studied with caution, since they consider only one parameter a time and it is known that therapeutic results can be influenced by several factors, including the following.
(i) Drug employed. When the percentages of cyst modifications after treatment were compared, for our patients albendazole was significantly (P < 0.001) more effective than mebendazole in the treatment of whole hydatid cysts and liver cysts (50.6 versus 77.9% and 46.5 versus 80.1%, respectively); furthermore, the cysts treated with albendazole showed degenerative modifications in shorter periods than the cysts treated with mebendazole (means of 1 to 3 versus 3 to 6 months).
In our experience, the effectiveness of albendazole in the treatment of liver cysts was greater than in other studies reported (8) . This may be correlated to the different dosage schedules used; in fact, in our series, albendazole was administered for uninterrupted cycles of 3 months, while other investigators used three cycles of therapy of 1 month with 15-day suspensions of therapy between cycles.
In our study, uninterrupted administration of albendazole was preferred since, in our opinion, intermittent administration could be more useful to the parasite than to the host.
( (4, 14, 21, 22, 27, 31) regarding the findings of degenerative modifications in the cysts treated with benzoimidazole carbamates, relapses, and side effects. On the other hand, in our study, albendazole showed significantly more effective results than mebendazole in liver cysts, which differs from the findings of other authors (8) . Finally, no positive correlation between drug levels and the effectiveness of therapy was found in our investigation (9) , in disagreement with the findings of other authors (21, 22, 24, 27) .
Benzoimidazole carbamates sometimes have a parasitocidal and sometimes a parasitostatic action, as suggested by the relapses frequently observed after suspension of treatment, as if the drugs can sterilize and stop the growth of echinococci but not completely kill them (2, 17, 20, 24) .
After medical treatment, hydatid cysts show the same morphologic changes that can occur in the natural development of these cysts; nevertheless, the frequency of such changes is undoubtedly much higher than that observed for untreated cysts. Furthermore, these degenerative alterations take place and progress over shorter periods.
The treatment of cysts with further cycles of benzoimidazole carbamates after relapses proved to be effective in about 95% of the cases. Some cysts showed signs of recurrence more than once during follow-up (up to eight times in one case of a subcutaneous cyst), but they maintained equal sensitivity to further treatment.
Concerning the relationship between surgical and medical therapy of patients with hydatid disease, surgery should be indicated for patients with complications (infection or rupture of cysts or symptoms of compression or obstruction). 
